Treatment patterns and outcomes in advanced clear cell sarcoma and gastrointestinal neuroectodermal tumors

Clicks: 8
ID: 329704
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #57 of 62 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Clear cell sarcoma (CCS) and gastrointestinal neuroectodermal tumor (GNET) are ultra-rare soft tissue sarcomas with no established standard of care for advanced disease. Data evaluating outcomes of systemic therapy remain limited. We aimed to evaluate systemic therapy in patients with metastatic CCS/GNET treated at a tertiary referral institution. METHODS: This is a retrospective, single-institution study of patients with metastatic CCS/GNET diagnosed between January 2000 and May 2025. The primary objective was to describe patterns of systemic therapy use and secondary endpoints included overall survival (OS) and real-world progression free survival (rwPFS). Survival outcomes were estimated using the Kaplan-Meier method. Hazard ratios were estimated using Cox proportional hazards models. Exploratory analyses evaluated outcomes by treatment class. RESULTS: Sixty-six patients were included; 55 received systemic therapy. Median follow-up was 192 months, and patients received a median of two treatment lines with heterogeneous sequencing. Median OS was 18 months (95%CI 13.6-28.0). In first-line analyses, tyrosine kinase inhibitors (TKI) based therapy and immune-checkpoint inhibitors (ICI) was associated with improved OS compared with doxorubicin-based chemotherapy (TKI: HR 0.33, 95% CI 0.14-0.79; p = 0.01, ICI: HR 0.39, 95% CI 0.10-0.94; p = 0.04). Median first-line rwPFS was 3.8 months (95% CI, 2.9-6.3), with no significant differences between treatment classes. Non-doxorubicin-based chemotherapy was associated with shorter rwPFS compared with doxorubicin regimens (HR 4.1, 95% CI, 1.71-9.83; p < 0.001). CONCLUSIONS: Metastatic CCS/GNET is highly aggressive with limited effective systemic options. Outcomes remain poor, highlighting the need for novel therapies and collaborative studies.
Reference Key
openalex_W7214148658 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Adel Shahnam, Daniel Reinhorn, Mrinal M. Gounder, Rhoena Desir-Camille, Olayode Babatunde, Ciara M Kelly, Lauren Baker Banks, Viswatej Avutu, Ping Chi, Sujana Movva, Mark A Dickson, Damon R. Reed, Mary L Keohan, Cristina R Antonescu, Meera Hameed, Konstantinos Linos, Narasimhan Agaram, Robert G. Maki, Sandra P D’Angelo, T. William
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag096
URL
https://doi.org/10.1093/jncics/pkag096
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.